Tuesday, March 3, 2015

Roth starts Zosano Pharma at buy

Roth starts Zosano Pharma at buy

February 23, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Zosano Pharma (NASDAQ:ZSAN) with a “buy” rating and price target of $20. The stock closed at $11.09 on Friday. Zosano Pharma has a microneedle “patch” platform that provides injection-like results with a more tolerable delivery vehicle. “The impetus for our buy rating is the potential of the […]

Elemer Piros joins Roth biotech team

Elemer Piros joins Roth biotech team

February 19, 2015 by · Leave a Comment 

Tweet Elemer Piros has joined Roth Capital Partners as a senior research analyst covering the biotechnology sector. Prior to joining Roth, Dr. Piros was interim CEO of eMMUNITY, an immunotherapy startup company. He was previously a senior biotechnology analyst at Rodman & Renshaw and Burrill Securities. Dr. Piros was ranked as the No. 1 biotechnology […]

Roth starts Spark Therapeutics at buy

Roth starts Spark Therapeutics at buy

February 19, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Spark Therapeutics (NASDAQ:ONCE) with a “buy” rating and 12-month price target of $71, saying Spark’s gene therapy platform could revolutionize the treatment of genetic disorders. The stock closed at $46 on Wednesday. “Spark Therapeutics, a less than two-year old company, could become the first to secure FDA […]

Roth resumes coverage of Neptune at buy

Roth resumes coverage of Neptune at buy

January 30, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Neptune Technologies & Bioressources (NASDAQ:NEPT; TSX:NTB) with a “buy” rating and $5 price target. The stock closed at $1.83 on Thursday. Neptune is a leading provider of krill oil (omega-3 supplements) with its premium product, Neptune Krill Oil (NKO). “With a new state-of-the-art manufacturing plant, and a […]

Roth starts Titan Pharma at buy

Roth starts Titan Pharma at buy

January 20, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Titan Pharmaceuticals (OTCBB:TTNP) with a “buy” rating and a price target of $1.25. The stock closed at 47 cents on Monday. “The impetus for our buy rating is the potential of the company’s developmental Probuphine six-month implant of buprenorphine for the treatment of opioid dependence,” writes analyst […]

The Joint Corp. sets aggressive expansion plan

The Joint Corp. sets aggressive expansion plan

January 6, 2015 by · Leave a Comment 

Tweet Fresh from a $20-million IPO in November, The Joint Corp. (NASDAQ:JYNT), a franchisor of some 236 chiropractic clinics in 25 states, plans to more than double the number of clinics in its chain as part of a national expansion over the next five years. “Our strategy is to aggressively grow our already proven, profitable […]

Roth starts Hyperion Therapeutics at buy

Roth starts Hyperion Therapeutics at buy

November 3, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Hyperion Therapeutics (NASDAQ:HPTX) with a “buy” rating and price target of $34. The stock closed at $24.30 on Friday. “Hyperion is well positioned to expand its GI-focused rare/orphan disease franchise by leveraging key insights in the role of ammonia control in urea cycle disorders (UCD) and hepatic encephalopathy (HE),” […]

Roth names John Chambers as vice chairman

Roth names John Chambers as vice chairman

October 30, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has named John Chambers as vice chairman in addition to his ongoing role as head of healthcare investment banking, a position he has held since joining Roth 2009. Mr. Chambers and his team has assisted Roth’s healthcare clients in raising over $8-billion in approximately 220 transactions since 2009. “John is an […]

Roth adds MEI Pharma to Focus List, ups price target to $22

Roth adds MEI Pharma to Focus List, ups price target to $22

October 16, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has added “buy-rated” MEI Pharma (NASDAQ:MEIP) to its Focus List and raised its price target to $22 from $20. The stock closed at $7.68 on Wednesday. Analyst Joseph Pantginis writes that MEI is well positioned with its lead oral HDAC inhibitor, pracinostat, for the treatment of acute myeloid leukemia (AML) and […]

Roth resumes coverage of XOMA at buy

Roth resumes coverage of XOMA at buy

October 10, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of XOMA (NASDAQ:XOMA) with a “buy” rating and $9 price target. The stock closed at $3.72 on Thursday. “We believe data lock is imminent on the ongoing Phase 3 EYEGUARD-B study of gevokizumab in Behçet’s disease uveitis, with top-line data expected around year-end,” writes analyst Ed Arce. “Given […]

Next Page »

Email Newsletters with Constant Contact
Google+